All lobbying filings

PFIZER INC.

PFIZER INC. filed a Q1 report for PFIZER INC. on April 21, 2025.

Lobbying for PFIZER INC.

All filings by PFIZER INC. · Everything PFIZER INC. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Expenses

$4,240,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Budget/Appropriations

H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 Budget Reconciliation

Health Issues

S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs

Medicare/Medicaid

S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - Epic Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act HR 946 - ORPHAN Cures Act PBM Reform Medicaid Prescription Drug Access

Taxation/Internal Revenue Code

H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 VICP Reform and Excise Tax Tax Cuts and Jobs Act (TCJA) Comprehensive Corporate Tax Reform

Trade (domestic/foreign)

HR 2213 - Authorize the President to Enter Into Trade Agreements for the Reciprocal Elimination of Duties or Other Import Restrictions with Respect to Medical Goods Medical Supply Chain Resiliency Act International Supply Chain Tariffs Non-Tariff Trade Barriers

Bills named in this filing 4

H. Con. Res. 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
H.R. 946
ORPHAN Cures Act
H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
H.R. 2213
Medical Supply Chain Resiliency Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.